These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34549875)

  • 1. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer.
    Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X
    IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
    Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
    Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
    Li Y; Meng L; Shi T; Ren J; Deng Q
    Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
    Pan J; Chen Y; Mo C; Wang D; Chen J; Mao X; Guo S; Zhuang J; Qiu S
    PLoS One; 2014; 9(3):e92815. PubMed ID: 24664224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
    Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
    Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
    Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
    Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
    Böttcher R; Dulla K; van Strijp D; Dits N; Verhoef EI; Baillie GS; van Leenders GJ; Houslay MD; Jenster G; Hoffmann R
    Oncotarget; 2016 Oct; 7(43):70669-70684. PubMed ID: 27683107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
    Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
    Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HCG18 and MCM3AP-AS1 That Associate With Bone Metastasis, Poor Prognosis and Increased Abundance of M2 Macrophage Infiltration in Prostate Cancer.
    Chen Y; Chen Z; Mo J; Pang M; Chen Z; Feng F; Xie P; Yang B
    Technol Cancer Res Treat; 2021; 20():1533033821990064. PubMed ID: 33596783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
    Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
    Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant
    Bjerre MT; Strand SH; Nørgaard M; Kristensen H; Rasmussen AK; Mortensen MM; Fredsøe J; Mouritzen P; Ulhøi B; Ørntoft T; Borre M; Sørensen KD
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications.
    Lin YZ; Liu WH; Wu YP; Cai H; Zheng QS; Wei Y; Xu N; Xue XY
    Int J Immunopathol Pharmacol; 2024; 38():3946320241240706. PubMed ID: 38712735
    [No Abstract]   [Full Text] [Related]  

  • 20. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
    Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
    J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.